<sup>131</sup>Ⅰ治疗分化型甲状腺癌的现状和进展

胡莹莹; 蒋宁一

¹³¹Ⅰ治疗分化型甲状腺癌的现状和进展

胡莹莹 , 蒋宁一

文章导航 > 国际放射医学核医学杂志 > 2006, 30 > 6: (343-346)

引用本文:

Citation:

¹³¹Ⅰ治疗分化型甲状腺癌的现状和进展

胡莹莹,
蒋宁一^,

510120 广州, 中山大学附属第二医院核医学科

通讯作者: 蒋宁一, ningyij@163.net

中图分类号: R817.5

Radiodione treatment of differentiated thyroid cancer: current status and future prospects

HU Ying-ying,
JIANG Ning-yi^,

Nuclear Medicine Department, The Second Affiliated Hospital of Zhaongshan University, Guangzhou 510120, China

Corresponding author: JIANG Ning-yi, ningyij@163.net

CLC number: R817.5

摘要: 分化型甲状腺癌(DTC)包括乳头状癌和滤泡状癌,占甲状腺恶性肿瘤的90%以上。DTC恶性程度不高,其肿瘤细胞保留了甲状腺细胞的摄碘功能,目前常用"手术+¹³¹Ⅰ治疗+甲状腺素抑制"的综合疗法治疗DTC,提高了DTC患者的生存率,但在DTC病变发展过程中,肿瘤细胞有失分化的趋势,其摄取碘的功能降低甚至消失。目前针对DTC治疗的研究趋势主要包括基因重组人促甲状腺激素的临床应用,维甲酸的诱导再分化及钠燃运体基因的研究。
- 碘放射性同位素 /
- 甲状腺肿瘤 /
- 综合疗法
Abstract: More than 90% of primary thyroid cancers are differentiated papillery or follicular types. The popular treatment of differentiated thyroid carcinoma(DTC) consist of surgery, radioiodine ablation and thyroid stimulating hormone suppressive therapy, which increase clinical benefit rate. During tumor progression, cellular de-differentiation occurs in up to 30% of cases and usually result in the loss of iodine uptake. The current resercbes aiming to improve treatment effect of DTC including clinical application of rhTSH, retinoic acid inducement to re-differentiation and gene therapy on sodium-iodide symporter.
- Iodine radioisotopes /
- Thyroid neoplasms /
- Combined modality therapy
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	刑家骝.131碘治疗甲状腺疾病.北京:人民卫生出版社,2002.272-307.
[2]	Patel A, Jhiang S, Dogra S, et al. Differentiated thyroid carcinoma that express sediun-iodine symporter have a lower risk of recurrence for children and adolescents. Pediat Res, 2002, 52(5):737-744.
[3]	Kalinyak JE, McDougall IR Whole-body scanning with radionuclides of iodine and the controversy of thyroid stunninng. Nucl Med Commun, 2004, 25(9):883-889.
[4]	Chen CH, Chen JF, Yang BY, et al. Bone mineral density in woman receiving thyroxine suppressive therapy for differentiated thyroid carcinoma. J Formos Med Assoc, 2004, 103(6):442-447.
[5]	Lazar V, Bidart JM, Caillou B, et al. Expression of the Na⁺/I^- symporter gene in human thyroid tumors:a comparasin study with other thyroid specific genes. J Clin Endocrinol Metab, 1999, 84(9):3228-3234.
[6]	Mazzaferri EL, Bobbins B J, Spencer CA, et al. A consensus report of the role of serun thyglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab, 2003, 88(4):1433-1441.
[7]	田蓉,潘明志,匡安仁.Tg升高¹³¹I显像阴性的甲状腺癌患者¹³¹I疗效评价.中华核医学杂志,2003,23(1):27-29.
[8]	Saito T, Endo J, Kawaguchi A, et al. Increased expression of the Sodium/iodine symporter in papillary thyroid carcinomas. J Clin Invest, 1998, 101(7):1296-1300.
[9]	Pacini F, Capezzone M, Elisei R, et al. Diagnostic 131-iedine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated senun Tg levels after initial treatment. J Clin Endocrinol Metab, 2002, 87(4):1499-1501.
[10]	Simon D, Koehrle J, Reiners C, et al. Redifferentiation therapy with retinoids:therapeutic option for advanced follicular and advanced follicular and papillary thyroid carcinoma. World J Surg,1998, 22(6):569-574.
[11]	Kohlfuerst S, Igerc L Lind P. Recombinant human thyrotropin is helpful in the follow-up and ¹³¹Ⅰ therapy of patients with thyroid cancer, a report of the results and benefits using recombinant human thyrotropin in clinical routine. Thyroid, 2005, 15(4):371-376.
[12]	David A, Blotta A, Rossi R, et al. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotrepin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid, 2005, 15(3):267-273.
[13]	Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma:a comprehensive review. Endocr Relat Cancer, 2005, 12(1):49-64.
[14]	Loffler M, Weckesser M, Franzius C, et al. lodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma. Nuldearmedizin, 2003, 42(6):240-243.
[15]	Menzel C, Kranert WT, Dobert N, et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life (131)Ⅰ. J Nucl Meal, 2003, 44(7):1065-1068.
[16]	Coelho SM, Vaisman M, Carvalho DP. Tumour redifferentiation effect of retinoic acid:a novel therapeutic approach for advanced thyroid cancer. Curt Phann Des, 2005, 11(19):2525-2531.
[17]	Cho JY. A transporter gene (sodium iodine smporter) for dual purposes in gene therapy:imaging and therapy. Curr Gene Ther,2002, 2(4):393-402.
[18]	Venkatarman GM, Yatin M, Marcinek R, et al. Restoration of iodine uptake in differentiated thyroid carcinoma:relalionship to human Na⁺/I^- symporter gene methylatlon status. J Clin Endocrinol Metab, 1999, 84(7):2449-2457.
[19]	Zarnegar R, Bnmaud L, Kanauchi H, et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using trichostatin A (TSA), a histone deacetylase inhibitor.Surgery, 2002, 132(6):984-990.
[20]	Dohan O, Baloch Z, Banrevi Z, et al. Rapid communication:predominant intracellular overexpression of the Na⁺/I^- symporter (NIS) in a large sampling of thyroid cancer cades. J Clin Endocrinol Metab, 2001, 86(6):2697-2700.

[1]	刘康其 , 周海中 . 放射性药物联合双膦酸盐类药物治疗肿瘤骨转移研究现状. 国际放射医学核医学杂志, 2019, 43(2): 166-170. doi: 10.3760/cma.j.issn.1673-4114.2019.02.012
[2]	易艳玲 , 卓维海 . ¹³¹I治疗甲状腺肿瘤患者出院剂量指导水平分析. 国际放射医学核医学杂志, 2008, 32(6): 372-375.
[3]	杨坤禹 , 胡豫 . 抗肿瘤血管新生联合放射治疗研究进展. 国际放射医学核医学杂志, 2006, 30(2): 122-126.
[4]	郭睿 , 李彪 . 钠碘同向转运体基因介导放射性碘治疗肿瘤的研究进展. 国际放射医学核医学杂志, 2010, 34(3): 147-151. doi: 10.3760/cma.j.issn.1673-4114.2010.03.005
[5]	刘建宇 , 朱宗平 , 石德道 , 郑飞波 . 放射性碘难治性分化型甲状腺癌去分化分子机制及再分化治疗的分子靶向药物. 国际放射医学核医学杂志, 2023, 47(2): 123-126. doi: 10.3760/cma.j.cn121381-202205003-00267
[6]	李宇轩 , 张禹 , 林志毅 , 苏耀东 , 石远颖 , 陈文新 . ⁹⁹Tc^m-3PRGD₂ SPECT/CT显像在不摄碘进展性放射性碘难治性分化型甲状腺癌中的诊断价值. 国际放射医学核医学杂志, 2023, 47(5): 281-288. doi: 10.3760/cma.j.cn121381-202301001-00304
[7]	冯成涛 , 张海波 , 郑皓 , 王梓延 , 邓赟 , 赵继华 , 朱高红 . ¹³¹I-PAMAM(G5.0)介导靶向肽在甲状腺髓样癌模型中的实验研究. 国际放射医学核医学杂志, 2019, 43(6): 528-537. doi: 10.3760/cma.j.issn.1673-4114.2019.06.007
[8]	刘雪辉 , 高志民 . 自主功能性甲状腺结节的临床诊疗进展. 国际放射医学核医学杂志, 2020, 44(12): 780-785. doi: 10.3760/cma.j.cn121381-201910002-00108
[9]	岳园芳 , 刘建井 , 尹国涛 , 戴东 , 徐文贵 . DTC患者¹³¹I治疗后左甲状腺素钠片最佳初始剂量预测模型探究. 国际放射医学核医学杂志, 2022, 46(4): 197-202. doi: 10.3760/cma.j.cn121381-202111005-00171
[10]	陈志军 , 谭丽玲 , 王文俊 , 周爱清 . ¹³¹I联合¹²⁵I粒子治疗难治性甲状腺癌骨转移一例. 国际放射医学核医学杂志, 2017, 41(1): 76-78. doi: 10.3760/cma.j.issn.1673-4114.2017.01.015

点击查看大图

计量

文章访问数: 1483
HTML全文浏览量: 95
PDF下载量: 3

¹³¹Ⅰ治疗分化型甲状腺癌的现状和进展

胡莹莹
蒋宁一^,

通讯作者: 蒋宁一, ningyij@163.net

510120 广州, 中山大学附属第二医院核医学科

收稿日期: 2005-12-19

关键词:

摘要: 分化型甲状腺癌(DTC)包括乳头状癌和滤泡状癌,占甲状腺恶性肿瘤的90%以上。DTC恶性程度不高,其肿瘤细胞保留了甲状腺细胞的摄碘功能,目前常用"手术+¹³¹Ⅰ治疗+甲状腺素抑制"的综合疗法治疗DTC,提高了DTC患者的生存率,但在DTC病变发展过程中,肿瘤细胞有失分化的趋势,其摄取碘的功能降低甚至消失。目前针对DTC治疗的研究趋势主要包括基因重组人促甲状腺激素的临床应用,维甲酸的诱导再分化及钠燃运体基因的研究。